Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 4.6% - Should You Sell?

Key Points

• Polaryx Therapeutics shares fell 4.6% to $1.85 in mid-day trading, with volume about 51% above the average. The company’s market capitalization is approximately $92.2 million, and its stock remains below both its 50-day and 200-day moving averages.
• Analyst sentiment is mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $7.67. Ratings range from “Strong Buy” and “Buy” to “Hold” and “Sell,” highlighting significant uncertainty.
• The clinical-stage biotechnology company reported a quarterly loss of $0.03 per share, beating estimates for a $0.05 loss. Analysts expect a full-year loss of approximately $0.22 per share as Polaryx develops therapies for rare pediatric lysosomal storage disorders.

Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report)'s stock price fell 4.6% during mid-day trading on Friday. The stock traded as low as $1.84 and last traded at $1.85. Approximately 42,788 shares were traded during mid-day trading, an increase of 51% from the average daily volume of 28,279 shares. The stock had previously closed at $1.94.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Raymond James Financial assumed coverage on Polaryx Therapeutics in a report on Thursday, August 13th. They issued a "strong-buy" rating and a $6.00 target price for the company. Weiss Ratings restated a "sell (e)" rating on shares of Polaryx Therapeutics in a research report on Monday, September 28th. Zacks Research upgraded Polaryx Therapeutics to a "hold" rating in a research report on Friday, July 10th. HC Wainwright initiated coverage on shares of Polaryx Therapeutics in a research note on Thursday, July 9th. They set a "buy" rating and a $7.00 price objective for the company. Finally, Wall Street Zen raised shares of Polaryx Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $7.67.

Polaryx Therapeutics Stock Down 4.6%

The company's 50 day simple moving average is $2.03 and its 200-day simple moving average is $2.81. The firm has a market cap of $92.22 million and a P/E ratio of -23.12.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. Equities research analysts predict that Polaryx Therapeutics, Inc. will post -0.22 EPS for the current year.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.